Neuroone Medical Technologies (NMTC) Net Equity Issued and Repurchased (2013 - 2025)

Neuroone Medical Technologies' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $9.2 million for Q2 2025.

• Quarterly Net Equity Issued and Repurchased rose 446.5% year-over-year to $9.2 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $8.8 million (up 62.54% YoY) and the FY2024 annual result came in at $836777.0, down 67.22% from the prior year.
• Net Equity Issued and Repurchased was $9.2 million for Q2 2025 at Neuroone Medical Technologies, up from -$4.2 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $9.2 million in Q2 2025 and bottomed at -$4.2 million in Q3 2024.
• A 4-year average of $1.7 million and a median of $1.7 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased rose 3.63% — and 2025, when it surged 446.5%.
• Neuroone Medical Technologies' Net Equity Issued and Repurchased stood at -$1.3 million in 2021, then surged by 387.04% to $3.8 million in 2023, then tumbled by 210.19% to -$4.2 million in 2024, then surged by 319.2% to $9.2 million in 2025.
• Business Quant data shows NMTC's Net Equity Issued and Repurchased at $9.2 million in Q2 2025, -$4.2 million in Q3 2024, and $1.7 million in Q2 2024.